Report Highlights

Substance Abuse Treatment in the U.S.: Market Overview

The U.S. substance abuse treatment market was valued at USD 45.2 billion in 2024 and is forecast to reach USD 71.5 billion by 2032. Its structure reflects a mixed economy: public payers finance a large share of care through Medicaid, the Substance Use Prevention, Treatment, and Recovery Services Block Grant, and State Opioid Response grants, while private operators deliver most residential and outpatient capacity. Medicaid remains the largest single payer.

Government dominates financing and standard-setting, while the private sector leads on capacity and digital delivery. Opioid Treatment Programs, licensed under 42 CFR Part 8, operate within a federally regulated core. Telehealth platforms such as Ria Health and Bicycle Health expanded outpatient reach after 2020, and Acadia Healthcare and American Addiction Centers concentrate residential beds. Nonprofit providers such as Hazelden Betty Ford retain a large share of premium inpatient care, and accreditation by CARF International remains a commercial differentiator.

Policy-Driven Growth in U.S. Substance Abuse Treatment

The SUPPORT for Patients and Communities Act (Public Law 115-271, October 2018) expanded telehealth flexibilities for substance use treatment, while the Consolidated Appropriations Act 2023 eliminated the DATA 2000 X-waiver, allowing any DEA-registered prescriber to dispense buprenorphine for opioid use disorder. This removed a prescribing licensure barrier and widened the office-based provider pool, which translates directly into higher outpatient admissions. State Opioid Response grants, administered by SAMHSA, add roughly USD 1.5 billion annually to state treatment budgets.

The National Opioid Settlement, finalized in 2021 with distributors McKesson, Cardinal Health and Cencora and manufacturer Johnson and Johnson, directs roughly USD 50 billion over 18 years to states and localities for treatment and recovery. Settlement funds flow through state abatement accounts, so counties procure residential beds and medication-assisted treatment directly. Parity enforcement under the Mental Health Parity and Addiction Equity Act compels commercial insurers to cover these services on terms comparable to medical care, supporting private-pay volume.

Regulatory Barriers and Compliance Costs

Patient-record confidentiality under 42 CFR Part 2, administered by SAMHSA, imposes distinct compliance costs on treatment operators. The February 2024 final rule aligned Part 2 with HIPAA and allows a single consent for future uses and disclosures, but providers must reconfigure records systems and retrain staff before the compliance date of February 16, 2026. Smaller independent clinics without dedicated compliance staff bear this burden most heavily, while large chains absorb it within existing information technology budgets.

State licensure is the second barrier, administered by state health departments; California's Department of Health Care Services, for example, licenses residential treatment facilities under Title 9 of the California Code of Regulations, and new-facility approvals can take several months. Telemedicine prescribing of controlled substances adds another constraint: DEA flexibilities were extended through December 31, 2025, and buprenorphine prescribing remains subject to federal registration rules that smaller providers must navigate.

Policy-Created Opportunities in the U.S.

The CCBHC Medicaid Demonstration, jointly run by SAMHSA and CMS, pays certified community behavioral health clinics a prospective bundled rate for integrated substance use and mental health services. SAMHSA and CMS added ten states to the demonstration in 2024, creating demand for providers that can meet the program's crisis and care coordination standards. Operators able to certify early secure bundled-rate revenue across multiple payer categories.

Section 1115 reentry waivers, which CMS has approved in several states, allow Medicaid to cover substance use services for incarcerated individuals in the 30 days before release. Medicare coverage of opioid treatment program services, enabled by the SUPPORT Act, opens a federal payer channel for OTP services alongside Medicaid and commercial contracts. Together these mechanisms create a predictable pipeline for transitional and medication-assisted treatment capacity.

Market at a Glance

Leading Market Participants

• Acadia Healthcare
• American Addiction Centers
• Hazelden Betty Ford Foundation
• Recovery Centers of America
• Caron Treatment Centers
• Ria Health
• Bicycle Health
• Workit Health
• BayMark Health Services
• Ophelia Health

Regulatory and Policy Environment

The principal statute is the SUPPORT for Patients and Communities Act (Public Law 115-271), administered through HHS, with SAMHSA responsible for grant administration and 42 CFR Part 2 confidentiality oversight. Medicaid coverage is governed by Title XIX of the Social Security Act, with CMS approving Section 1115 demonstrations and institutions for mental diseases exclusion waivers. The Mental Health Parity and Addiction Equity Act of 2008 (Public Law 110-343), enforced by the Departments of Labor, Health and Human Services, and the Treasury, requires parity for substance use benefits.

Upcoming changes are concrete. Part 2 compliance becomes mandatory on February 16, 2026, and the DEA's special registration proposal, published in January 2025, would govern telemedicine prescribing of controlled substances once flexibilities expire at the end of 2025. Compared with Canada, where opioid agonist therapy operates within provincial health legislation under a federal framework, the U.S. model layers federal, state and payer rules, creating higher administrative overhead but broader competitive entry.

Long-Term Policy Outlook for U.S. Substance Abuse Treatment

By 2032, Part 2 harmonization with HIPAA will have reshaped records infrastructure across the sector, and the DEA special registration framework will determine which telehealth prescribers can hold buprenorphine and stimulant authority. Opioid settlement disbursements, scheduled over 18 years, will taper in later years, forcing operators to replace settlement-funded contracts with Medicaid and commercial revenue. Providers that diversify payer mix before 2030 will hold margin, while those dependent on one-time abatement funds face contraction.

Medicaid policy will be the decisive variable, as states weigh expansion of Section 1115 reentry waivers and continuous-coverage provisions against fiscal constraints. Market growth to USD 71.5 billion by 2032 depends on whether payers reimburse residential stabilization and medication-assisted treatment at rates that sustain operators such as Recovery Centers of America, rather than pushing volume into lower-cost outpatient settings.